

Ruth Vera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7910681/publications.pdf>

Version: 2024-02-01

30
papers

1,095
citations

566801

15
h-index

476904

29
g-index

35
all docs

35
docs citations

35
times ranked

1725
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. <i>Clinical and Translational Oncology</i> , 2022, 24, 112-126.	1.2	12
2	Future care for long-term cancer survivors: towards a new model. <i>Clinical and Translational Oncology</i> , 2022, 24, 350-362.	1.2	2
3	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. <i>Clinical and Translational Oncology</i> , 2022, 24, 968-980.	1.2	3
4	The Determination of a Consensus Nutritional Approach for Cancer Patients in Spain Using the Delphi Methodology. <i>Nutrients</i> , 2022, 14, 1404.	1.7	3
5	Clinical landscape of LAG-3-targeted therapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100079.	0.2	37
6	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
7	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. <i>British Journal of Cancer</i> , 2022, 126, 1168-1177.	2.9	9
8	Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. <i>Clinical and Translational Oncology</i> , 2021, 23, 1520-1528.	1.2	4
9	Hyperprogressive Disease: Main Features and Key Controversies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3736.	1.8	18
10	Understanding LAG-3 Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5282.	1.8	78
11	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 823-834.	1.2	29
12	TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2020, 22, 1423-1424.	1.2	0
13	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 586907.	2.2	40
14	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. <i>Cancers</i> , 2020, 12, 2181.	1.7	9
15	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. <i>Cancers</i> , 2020, 12, 2259.	1.7	6
16	Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. <i>Clinical and Translational Oncology</i> , 2020, 22, 2253-2263.	1.2	9
17	LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, S242-S243.	0.6	31
18	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. <i>Cancers</i> , 2020, 12, 344.	1.7	60

#	ARTICLE	IF	CITATIONS
19	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. <i>International Journal of Colorectal Disease</i> , 2020, 35, 739-746.	1.0	12
20	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	1.6	48
21	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2411.	1.8	28
22	Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapy. <i>EMBO Molecular Medicine</i> , 2020, 12, e12706.	3.3	19
23	Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. <i>EMBO Molecular Medicine</i> , 2019, 11, e10293.	3.3	145
24	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1631.	1.8	59
25	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54.	1.2	40
26	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017, 20, 1818-1829.	2.9	220
27	Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. <i>Clinical and Translational Oncology</i> , 2017, 19, 498-507.	1.2	15
28	First-line bevacizumab and capecitabine+oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. <i>British Journal of Cancer</i> , 2014, 111, 241-248.	2.9	29
29	Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. <i>Clinical and Translational Oncology</i> , 2014, 16, 739-745.	1.2	18
30	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. <i>Annals of Oncology</i> , 2013, 24, 2342-2349.	0.6	89